Guadalupe Hayes-Mota

The intersection of artificial intelligence (AI) and biotechnology is revolutionizing the healthcare landscape, offering opportunities for venture capitalists (VCs) to drive innovation and achieve significant returns on investment. This article delves into the key trends in AI in biotech and provides actionable strategies for VCs to navigate this dynamic sector.

In the current era of artificial intelligence (AI) reshaping industries worldwide, integrating AI in healthcare, public policy, and business is paramount. Dr. Soroush Saghafian, the visionary founder and director of the Public Impact Analytics Science Lab (PIAS-Lab) at Harvard, is a key figure at this intersection.

In the evolving landscape of global healthcare, low- and middle-income countries (LMICs) are spearheading a transformative strategy reshaping the pharmaceutical market dynamics, strategically leveraging their collective purchasing power. This method transcends traditional financial tactics, representing a fundamental shift in global health practices towards sustainable and universal access to essential medicines. I speak from experience as I led the global departments of Fortune 500 companies… Show more

In the evolving landscape of global healthcare, low- and middle-income countries (LMICs) are spearheading a transformative strategy reshaping the pharmaceutical market dynamics, strategically leveraging their collective purchasing power. This method transcends traditional financial tactics, representing a fundamental shift in global health practices towards sustainable and universal access to essential medicines. I speak from experience as I led the global departments of Fortune 500 companies production and distribution of medicines. Show less

Integrating AI into healthcare transcends the mere adoption of new technologies; it necessitates cultivating an ecosystem where innovation can flourish. Here’s an expanded look at seven strategies to pave this future:

The biopharmaceutical industry stands on the cusp of a revolution, with artificial intelligence (AI) emerging as a transformative force in drug development. AI's ability to reduce the time and cost of bringing new drugs to market is not just a promise; it is becoming a reality. In this article, we delve into the ways AI is reshaping drug development, analyzing the mechanics behind each method and their future potential and then ranking them on their overall impact on the industry.

Given rapid changes and unpredictability, I've found that traditional business strategies often fall short of addressing the complexities of the modern market. As such, I developed a framework called "REVISE" that allows for adaptability and innovation in organizational strategy.

The global healthcare landscape is undergoing a significant transformation. Driven by the need to make healthcare more equitable, especially in low- and middle-income countries (LMICs), three innovative strategies are leading the charge: enhancing local pharmaceutical production, forming strategic partnerships, and pooling purchasing power. These initiatives are not just reshaping access to medicines but laying the groundwork for a more balanced and accessible global health system.

Chemotherapy drugs are among the top five categories experiencing the most pronounced shortages. The shortages those drugs are facing are deemed the most severe by 57% of pharmacists, who describe them as “critically impactful,” directly affecting patient care. More than 40% of healthcare system pharmacists report having to delay or cancel treatments or procedures due to drug shortages (ASHP 2023).

This scarcity has been further intensified by the global COVID-19 ­pandemic, emphasizing… Show more

Chemotherapy drugs are among the top five categories experiencing the most pronounced shortages. The shortages those drugs are facing are deemed the most severe by 57% of pharmacists, who describe them as “critically impactful,” directly affecting patient care. More than 40% of healthcare system pharmacists report having to delay or cancel treatments or procedures due to drug shortages (ASHP 2023).

This scarcity has been further intensified by the global COVID-19 ­pandemic, emphasizing the pressing need for a robust and agile supply chain in the life science industry. This article delves into the imperative of a well-functioning healthcare supply chain. It explores the potential of connecting complex global supply chains using supply chain control tower (SCCT) technology within the life science industry to expedite drug delivery to patients. Show less

The biopharmaceutical industry, valued at over $350 billion, is a cornerstone of global health innovation. The onset of the Covid-19 pandemic highlighted the industry's importance and the need for transparent, agile and connected supply chains. This article delves into strategies to enhance supply chain visibility in biopharma.

Pursuant to the Massachusetts Rare Disease Advisory Council (RDAC) charter, we present this summary of the prevalence of rare diseases in Massachusetts. The purpose of this document is to provide the legislature with an estimate of the proportion of Massachusetts residents affected by a rare disease. To the best of our knowledge, no other RDAC in the country has prepared a similar report estimating rare disease prevalence within their state.

Launching a biopharmaceutical company requires groundbreaking scientific research and substantial financial resources. At the same time, securing funding may seem daunting, but various strategies and ideas can greatly enhance your chances of successfully raising capital.

The unprecedented power of artificial intelligence (AI) is transforming the life sciences industry, opening doors to groundbreaking drug discoveries, innovative treatments and the promise of personalized medicine. As we harness AI's potential, addressing the ethical challenges that arise is imperative. This article outlines a new, robust ethical framework to ensure that AI serves humanity's best interests in life sciences while mitigating potential risks.

Every organization faces operational inefficiencies that can impede productivity, hinder growth and waste resources. As a leader, it's your responsibility to identify these inefficiencies and streamline processes to make your organization more efficient and effective. However, identifying the biggest operational inefficiencies can be a challenge, especially if you don't know where to look.

Invisible disabilities, as the name suggests, are disabilities that are not immediately apparent to others. Out of the 61 million adults in the United States who identify as having a disability of some kind, roughly 10% of those are invisible disabilities, which may include cognitive, neurological or mental health challenges
Here are three ways managers and leaders can actively support people with invisible disabilities:

The demand for Adderall has surged, with U.S. prescriptions rocketing to 41.4 million in 2021 — a 10.4% increase from 2020, according to IQVIA, a life sciences industry analytics provider. According to the Food and Drug Administration, the spike in demand, coupled with “intermittent manufacturing delays,” have created a national shortage. In an August 2022 survey, almost two-thirds of respondents said they were having trouble securing their Adderall.

With the increasing amount of available data, AI and machine learning have emerged as crucial tools for biopharmaceutical companies looking to remain competitive in the market. These tools are helping researchers speed up drug discovery, improve the clinical trial design and further personalize patient treatment. Here are five areas where I see AI and machine learning changing the biopharmaceutical industry.

A powerful movement is taking shape in the U.S. rare disease community that could transform the lives of millions of people. That’s right — millions. Even though a single rare disease may affect only a few individuals, there are several thousand of these problematic diseases that are difficult to identify and treat.